Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

病原菌快速鉴定及脓毒症诊断

• 批准号: 8619581
• 负责人: Ray Anthony Martino
• 金额: $ 96.12万
• 依托单位: ISENSE, LLC
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-15 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8619581
• 关键词: Academic Medical Centers; Accounting; Address; American; Antibiotic Therapy; Antibiotic susceptibility; Antibiotics; Blood; Blood Volume; Cause of Death; Clinic; Clinical; Collection; Culture Media; Detection; Device or Instrument Development; Diagnosis; Documentation; Drug Formulations; Goals; Grant; Growth; Hour; Human; Infection; Intensive Care Units; Laboratories; Libraries; Malignant neoplasm of lung; Malignant neoplasm of prostate; Measures; Methods; National Institute of Allergy and Infectious Disease; Organism; Patients; Performance; Phase; Predisposition; Process; Research; Sensitivity and Specificity; Sepsis; Site; Small Business Innovation Research Grant; Specimen; Speed; System; Systems Development; Technology; Testing; Time; United States; Variant; blind; commercialization; cost; cost effective; effective therapy; instrument; killings; malignant breast neoplasm; microorganism; pathogenic bacteria; prospective; public health relevance; software systems

DESCRIPTION (provided by applicant): Sepsis is the tenth-leading cause of death in the United States and the second-leading cause of death in the intensive care unit (ICU). Sepsis kills over 215,000 Americans each year - more than breast cancer, lung cancer, and prostate cancer combined. Rapid identification and determination of antibiotic susceptibility is critical fo effective treatment of infected patients. Phase I successfully demonstrated the iSense system's ability to discriminate bacterial species and strain 4-fold faster than legacy methods identify species alone. In Phase I iSense also successfully demonstrated the ability to determine strain-specific susceptibility to antibiotic therapy more than 1 day faster than conventional practice. Phase II aims address application to clinical human specimens along with development of instruments and media appropriate for commercial use. The ultimate goal of this research is to develop and commercially deploy an automated blood culture system that can diagnose sepsis, identify the species and strain of the infecting organism, and determine antibiotic susceptibility all in less than 24 hours from the lab's receipt of primary specimen.

描述（由申请人提供）：败血症是美国第十大死因，也是重症监护病房 (ICU) 的第二大死因。败血症每年导致超过 215,000 名美国人死亡 - 比乳腺癌、肺癌和前列腺癌的总和还多。快速识别和测定抗生素敏感性对于有效治疗感染患者至关重要。第一阶段成功证明了 iSense 系统区分细菌种类和菌株的能力比传统方法单独识别种类的速度快 4 倍。在第一阶段，iSense 还成功证明了确定菌株特异性对抗生素治疗敏感性的能力，比传统做法快 1 天以上。第二阶段的目标是解决临床人体标本的应用以及适合商业用途的仪器和介质的开发。这项研究的最终目标是开发并商业部署自动化血液培养系统，该系统可以在实验室收到原始样本后 24 小时内诊断脓毒症、识别感染生物体的种类和菌株并确定抗生素敏感性。